Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133⁺ Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy

Figure 2

Flow cytometric analysis of CD133⁺ cells. Representative example of purity testing as assessed by flow cytometric immunophenotyping. Upper panels (a and b) indicate the BM cell bulk before CliniMACS selection and lower panels (c and d) indicate the positive fraction of cells obtained after CliniMACS selection and overnight storage. Briefly population of interest is initially gated by a dual light scatter dot plot (panels a and c); CD34⁺/CD133⁺ double positive cells before and after selection are then identified and calculated by dual fluorescence dot plot analysis as indicated in panels (b) and (d), respectively.

(a)

(b)

(c)

(d)